Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class biologics for oncology applications. The company's proprietary platform engineers bifunctional antibodies that combine tumor-targeting precision with tumor microenvironment modulators. Its lead clinical program, ficerafusp alfa (BCA101), is an epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-b) ligand trap. This candidate is primarily being evaluated for the treatment of head and neck squamous cell carcinoma (HNSCC) and other squamous cell carcinomas. Originally established as a subsidiary of Biocon Limited, Bicara operates as an independent entity advancing its pipeline through late-stage clinical trials.
